Patent Law

PLI is hosting the above-titled conference in New York City on September 17, 2009 (along with groupcasts in Boston, Philadelphia and Pittsburgh and a live webcast) and in San Francisco on October 14, 2009.

This year?s program is totally new! Pharmaceutical and biotech patent law is an important and rapidly changing practice area and the program is designed to give you the information you need to maintain your practice edge.

Technological innovation, Federal Circuit appellate oversight, Congressional action and Supreme Court decisions have all driven significant changes in the law. Several different perspectives on many of the most pressing issues will be offered from experienced in-house and outside counsel.

Do not miss this opportunity to fully understand the impact of appellate decisions and the pending patent legislation on your pharmaceutical and biotechnology patent practice.

What You Will Learn

? The patentability of pharmaceutical products post-KSR v. Teleflex from the Federal Circuit and District Court perspectives

? Inequitable conduct in biotechnology and pharmaceutical patent cases; recent Supreme Court and Federal Circuit developments

? Section 112 developments regarding enablement and written description requirements: the impact of U.S. Patent and Trademark Office (USPTO) Written Description Guidelines

? Cutting-edge issues impacting your pharma and biotech patent prosecution practice

? Patent misuse and other issues in pharma and biotech licensing

? At the intersection of antitrust and pharma and biotech patent cases: unique issues that can arise and strategies to avoid antitrust liability

Faculty

Co-Chairs

    David K. Barr, Kaye Scholer LLP

    Daniel L. Reisner, Kaye Scholer LLP

Speakers

    Karen I. Boyd, Turner Boyd LLP

    Jennifer Gordon, Baker Botts L.L.P.

    Timothy R. Holbrook, Professor at Law, Emory University School of Law

    Lisa A. Schneider, Sidley Austin LLP

    Gerald Sobel, Kaye Scholer LLP

    Darryl L. Webster, Senior Patent Counsel, Wyeth

    Cynthia H. Zhang, Ph.D., Director, Intellectual Property, Gilead Sciences Inc

Program Attorneys

    John M. Mola, Practising Law Institute

More information and registration are available here.